Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial
- 1 June 2005
- journal article
- clinical trial
- Published by Elsevier in The Lancet Oncology
- Vol. 6 (6) , 369-376
- https://doi.org/10.1016/s1470-2045(05)70175-3
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response RateJournal of Clinical Oncology, 2004
- Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic CancerJournal of Clinical Oncology, 2004
- Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2003
- Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2003
- End Points and United States Food and Drug Administration Approval of Oncology DrugsJournal of Clinical Oncology, 2003
- Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297Journal of Clinical Oncology, 2002
- A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinomaAnnals of Oncology, 2002
- Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancerPublished by Elsevier ,1999
- Comprehensive Criteria for Assessing Therapy-Induced ToxicityCancer Investigation, 1989
- The memorial pain assessment card. A valid instrument for the evaluation of cancer painCancer, 1987